Immediate versus Delayed IUD Insertion after Uterine Aspiration
|
|
|
- Helen Clark
- 9 years ago
- Views:
Transcription
1 T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Immediate versus Delayed IUD Insertion after Uterine Aspiration Paula H. Bednarek, M.D., M.P.H., Mitchell D. Creinin, M.D., Matthew F. Reeves, M.D., M.P.H., Carrie Cwiak, M.D., M.P.H., Eve Espey, M.D., M.P.H., and Jeffrey T. Jensen, M.D., M.P.H., for the Post-Aspiration IUD Randomization (PAIR) Study Trial Group A BS TR AC T From the Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland (P.H.B., J.T.J.); the Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh (M.D.C., M.F.R.); and the Department of Epidemiology, University of Pittsburgh Graduate School of Public Health (M.D.C.) both in Pittsburgh; the Department of Gynecology and Obstetrics, Emory University, Atlanta (C.C.); and the Department of Obstetrics and Gynecology, University of New Mexico, Albuquerque (E.E.). Address reprint requests to Dr. Bednarek at the Department of Obstetrics and Gynecology, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd., UHN 50, Portland, OR 97239, or at [email protected]. This article ( /NEJMoa ) was updated on June 10, 2011, at NEJM.org. N Engl J Med 2011;364: Copyright 2011 Massachusetts Medical Society. BACKGROUND Intrauterine devices (IUDs) provide highly effective, reversible, long-term contraception that is appropriate for many women after first-trimester uterine aspiration. However, the effects of immediate versus delayed IUD insertion after uterine aspiration on rates of complications and IUD use are uncertain. METHODS We performed a randomized noninferiority trial involving women undergoing uterine aspiration for induced or spontaneous abortion at 5 to 12 weeks of gestation who desired an IUD. Subjects were randomly assigned (in a 5:6 ratio) to IUD insertion immediately after the procedure or 2 to 6 weeks afterward (delayed insertion). The primary outcome was the rate of IUD expulsion 6 months after IUD insertion; an expulsion rate 8 percentage points higher in the immediate-insertion group was defined as inferior. RESULTS Among 575 women who underwent randomization, an IUD was inserted in 100% (258 of 258) of the women in the immediate-insertion group and in 71.3% (226 of 317) of those in the delayed-insertion group (difference, 28.7 percentage points; 95% confidence interval [CI], 23.7 to 33.7). The 6-month expulsion risk was 5.0% (13 of 258 women) after immediate insertion and 2.7% (6 of 226) after delayed insertion (difference, 2.3 percentage points; 95% CI, 1.0 to 5.8), which was consistent with the predefined criterion for noninferiority. Six-month rates of IUD use were higher in the immediate-insertion group (92.3%, vs. 76.6% after delayed insertion; P<0.001). Adverse events were rare and did not differ significantly between groups. No pregnancies occurred in the immediate-insertion group; five occurred in the delayedinsertion group (P = 0.07), all in women who never received an IUD. CONCLUSIONS The 6-month rate of expulsion of an IUD after immediate insertion was higher than but not inferior to that after delayed insertion. Immediate insertion resulted in higher rates of IUD use at 6 months, without an increased risk of complications. (Funded by the Susan Thompson Buffett Foundation; ClinicalTrials.gov number, NCT ) 2208 n engl j med 364;23 nejm.org june 9, 2011
2 Timing of IUD Insertion after Uterine Aspiration More than half of all unintended pregnancies in the United States occur as a result of inconsistent or discontinued use of contraceptives. 1 Intrauterine devices (IUDs) provide safe, highly effective, long-term contraception, but they are underused. 2 Because IUDs do not require active use, once they have been inserted, and have a very low failure rate, their increased use has the potential to substantially reduce unintended pregnancies. 3 Immediate initiation of any contraceptive method after an abortion has been linked to a reduced risk of repeat abortion, 4 with immediate use of an IUD the most effective method for reducing this risk. 4,5 IUD placement immediately after uterine aspiration could eliminate the need for an additional visit and ensure effective contraception by the time ovulation resumes, as early as 2 to 3 weeks after the procedure. 6 Although many women would prefer immediate IUD insertion, 7 such insertions have been limited by concerns about increased rates of expulsion, uterine perforation, and infection and by concern about increased cost. One randomized trial comparing immediate insertion with delayed insertion of the Copper 7 IUD and several observational studies have shown low rates of perforation and infection when IUDs are inserted immediately after first-trimester uterine aspiration This approach, however, has not been evaluated in a randomized fashion for modern T-shaped IUDs. Furthermore, it is unclear whether an increase in IUD use with immediate insertion outweighs any potential increase in the expulsion rate. We designed the present trial to compare the rates of IUD expulsion, use, removal, and complications with immediate versus delayed IUD insertion after first-trimester uterine aspiration. Me thods Study Design Women were enrolled from May 2007 through December 2008 at four U.S. academic medical centers: Oregon Health and Science University (OHSU), University of Pittsburgh, Emory University, and the University of New Mexico. Enrollment sites included Planned Parenthood affiliates (in Portland, OR; Pittsburgh; and Albuquerque, NM), the Feminist Women s Health Center (at Emory University), a hospital-based abortion clinic (at Emory University), and academic faculty and resident offices (at OHSU and the University of Pittsburgh). The study was approved by the institutional review board at each institution. All subjects provided written informed consent before enrollment. The study was conducted in accordance with the protocol, which is available with the full text of this article at NEJM.org. Subjects Study participants were women 18 years of age or older who presented to participating sites requesting uterine aspiration for induced or spontaneous abortion between 5 and 12 weeks of gestation and who desired intrauterine contraception. Gestational age was determined by ultrasonography. Women were excluded if they had evidence of cervicitis or pelvic inflammatory disease, a uterine anomaly or fibroid distorting the cavity, known or suspected molar or ectopic pregnancy, or pelvic inflammatory disease or sexually transmitted infection within the previous 3 months. Neither osmotic dilators nor misoprostol was used for uterine aspiration or IUD insertion in this study. Study Procedures All subjects were screened for chlamydia immediately before uterine aspiration; subjects with positive results were treated with antibiotics according to Centers for Disease Control and Prevention guidelines. All subjects received perioperative prophylactic doxycycline at the time of uterine aspiration. Participants selected either a levonorgestrelreleasing IUD (Mirena, Bayer HealthCare Pharmaceuticals) or a copper IUD (ParaGard T380A, Teva Pharmaceuticals [formerly Duramed Pharmaceuticals]) before undergoing uterine aspiration. (For more information regarding the IUD selection process, see the Supplementary Appendix, available at NEJM.org.) All aspiration procedures were performed by a study investigator or a resident physician directly supervised by a study investigator. Randomization to either immediate IUD insertion (within 15 minutes after completion of the procedure) or delayed IUD insertion (2 to 6 weeks later) was accomplished by permuted-block randomization with random block sizes of 5 and 6, stratified by study center. Within each stratum, we randomly assigned subjects to immediate or delayed insertion in an overall ratio of approxi- n engl j med 364;23 nejm.org june 9,
3 T h e n e w e ngl a nd j o u r na l o f m e dic i n e mately 5:6 by using a ratio of 2:3 for a block size of 5 and a ratio of 3:3 for a block size of 6. Sequentially numbered, opaque envelopes containing cards with the computer-generated assignments were used. The envelopes were opened only after the aspiration procedure had been completed and the investigator had determined that immediate IUD insertion was feasible (i.e., the IUD could be safely placed if the subject was randomly assigned to immediate insertion). Subjects were excluded from randomization in cases of failure to confirm completion of the aspiration, hemorrhage, perforation, or any other condition that, in the opinion of the surgeon, precluded safe IUD insertion. All IUDs were placed by study investigators. This occurred after randomization in the case of subjects in the immediate-insertion group; those randomly assigned to delayed insertion were given appointments for follow-up visits. Subjects maintained daily diaries of bleeding, cramping or pain, and medication use from the day of the aspiration to 1 month after IUD insertion. Subjects were also asked to contact the study investigators regarding any unexpected symptoms or concerns related to the IUD. Duramed Pharmaceuticals donated ParaGard for the study. Neither Teva Pharmaceuticals nor the Susan Thompson Buffett Foundation, which provided grant support for the study, had access to the data or involvement in the study design, data collection or analysis, the writing of the manuscript, or the decision to submit the manuscript for publication. Follow-up Subjects were followed for 6 months after IUD insertion, with evaluations at 1, 3, and 6 months. The follow-up 1 month after insertion was conducted as an office visit that included review of the diary, completion of a questionnaire, a physical examination, and ultrasonographic verification of the intrauterine location of the IUD; clinicians assessing IUD location were aware of group assignments. Attempts were made to contact all subjects by telephone to complete a questionnaire 3 and 6 months after IUD insertion (or a scheduled appointment for subjects who did not return for IUD insertion). Subjects who had concerns about the IUD were seen at unscheduled visits by study investigators whenever possible. At all scheduled and unscheduled visits, subjects were evaluated for expulsion, continued use, or removal of the IUD, as well as for infection, pain, bleeding, pregnancy, and other IUD-related or medical concerns. Outcomes and Adverse Events Partial expulsion was defined as the presence of the IUD within the cervical canal, and complete expulsion was defined as the passage of the IUD out of the cervix entirely. Pelvic infection was considered to be present in women with purulent discharge, cervical or uterine tenderness, or a tender adnexal mass, with or without fever or leukocytosis. To ensure that all IUD-related events during the study period were identified, we reviewed medical records for subjects who reported care at nonstudy sites. Statistical Analysis The primary outcome was the rate of IUD expulsion 6 months after IUD insertion in women randomly assigned to undergo immediate or delayed insertion. Secondary outcomes included continued use of the IUD, removal (and reason for removal), reinsertion after expulsion or removal, and adverse events, including perforation, pelvic infection, and subsequent unintended pregnancy. All analyses were performed in the intentionto-treat population. Additional analyses were restricted to women with complete follow-up data at 6 months. The time from insertion to expulsion was evaluated with the use of the Kaplan Meier method. Logistic regression was used in separate models to assess prespecified potential predictors of IUD expulsion, use, and removal, including gravidity, parity, age, race or ethnic group, gestational age at uterine aspiration, reason for aspiration, IUD type, and study site. Variables that were associated with these outcomes in univariate analyses, with a P value of less than 0.10, were retained in the multivariable model, along with study site and randomization group. For all analyses, two-tailed P values of less than 0.05 were considered to indicate statistical significance. All analyses were completed with the use of SAS software, version 9.2 (SAS Institute). We based our sample-size calculation on a noninferiority test of two independent proportions 15,16 and defined an expulsion rate in the immediateinsertion group that was increased by 8 percentage points or more as inferior (upper bound of the 95% confidence interval for noninferiority, 11 percentage points). Using estimated 6-month expulsion rates of 6% with immediate insertion and 3% with delayed insertion and assuming an alpha 2210 n engl j med 364;23 nejm.org june 9, 2011
4 Timing of IUD Insertion after Uterine Aspiration 587 Women were screened and provided consent 9 Were excluded 2 Changed mind 3 Did not meet criterion for gestational age inclusion range 3 Had acute cervicitis on examination 1 Had suspected ectopic pregnancy 578 Were enrolled 3 Did not undergo randomization 2 Had an aspiration that was considered incomplete; both completed 6-mo follow-up (IUD not received) 1 Had uterine perforation and aspiration that was considered incomplete; she withdrew consent for further follow-up after 1-mo visit 575 Underwent randomization 258 Were assigned to immediateinsertion group 317 Were assigned to delayedinsertion group 258 (100%) Received IUD 222 (70.0%) Received IUD 95 (30.0%) Did not return for IUD insertion within 6 wk after aspiration 4 Received IUD outside of study Total of 226 (71.3%) received IUD Total of 91 (28.7%) did not receive IUD 39 (42.9%) Had logistic difficulty 27 (29.7%) Changed mind or chose a different method 8 (8.8%) Had partner, friend, or family who disapproved of IUD 3 (3.3%) Had other reason 14 (15.4%) Did not give reason 194 (75.2%) Completed 1-mo follow-up 188 of 226 (83.2%) Completed 1-mo follow-up 15 of 91 (16.5%) Completed 1-mo follow-up 12 Withdrew consent 178 (69.0%) Completed 3-mo follow-up 160 of 226 (70.8%) Completed 3-mo follow-up 27 of 91 (29.7%) Completed 3-mo follow-up 2 Withdrew consent 1 Withdrew consent 194 (75.2%) Completed 6-mo follow-up 191 of 226 (84.5%) Completed 6-mo follow-up 40 of 91 (44.0%) Completed 6-mo follow-up 231 of 317 (72.9%) Completed 6-mo follow-up Figure 1. Randomization and Follow-up of Study Participants. Women who missed an evaluation could return for later follow-up visits. n engl j med 364;23 nejm.org june 9,
5 T h e n e w e ngl a nd j o u r na l o f m e dic i n e level of 0.05 for a one-sided test, we calculated that a sample of 212 subjects in each group who underwent IUD insertion would result in 80% power. The sample size per group was increased to 266 to allow for a 20% rate of loss to follow-up over the 6-month period. In addition, the size of the delayed-insertion group was increased further to account for an estimated 15% nonreturn rate for delayed insertion, resulting in a sample of 266 subjects in the immediate-insertion group and 312 in the delayed-insertion group (5:6 ratio). R esult s Study Participants A total of 578 subjects were enrolled, but 3 did not undergo randomization because excessive bleeding after the uterine aspiration raised concern about incomplete aspiration. (These women were offered delayed IUD insertion.) Of the remaining 575 women, 317 were randomly assigned to delayed IUD insertion and 258 to immediate insertion (Fig. 1). Table 1. Baseline Characteristics of the Study Participants.* Characteristic Immediate IUD Insertion (N = 258) Delayed IUD Insertion (N = 317) P Value Age yr 27.5± ± Race or ethnic group no. (%) 0.06 White 163 (63.2) 180 (56.8) Black 57 (22.1) 77 (24.3) Hispanic 29 (11.2) 33 (10.4) Other 9 (3.5) 27 (8.5) Marital status no. (%) 0.81 Single 197 (76.4) 235 (74.1) Married 34 (13.2) 47 (14.8) Divorced, separated, or widowed 27 (10.5) 35 (11.0) Living with current partner no. (%) 126 (48.8) 162 (51.1) 0.59 Educational level no. (%) 0.19 High-school graduate or less 92 (35.7) 117 (36.9) Some college 105 (40.7) 144 (45.4) College graduate or postgraduate 61 (23.6) 56 (17.7) Annual household income, in U.S. $ no. (%) 0.73 Less than 10, (17.1) 60 (18.9) 10,000 to 29, (40.7) 115 (36.3) 30,000 to 49, (13.2) 47 (14.8) 50,000 or more 75 (29.1) 95 (30.0) Body-mass index 26.9± ± Gravidity no. (%) (20.5) 66 (20.8) 2 53 (20.5) 64 (20.2) 3 55 (21.3) 61 (19.2) 4 or more 97 (37.6) 126 (39.7) Parity no. (%) (35.3) 110 (34.7) 1 75 (29.1) 90 (28.4) 2 or more 92 (35.7) 117 (36.9) Previous abortions no. (%) (52.1) 178 (56.2) 1 85 (33.1) 85 (26.8) 2 or more 39 (15.2) 54 (17.0) 2212 n engl j med 364;23 nejm.org june 9, 2011
6 Timing of IUD Insertion after Uterine Aspiration Table 1. (Continued.) Characteristic Immediate IUD Insertion (N = 258) Delayed IUD Insertion (N = 317) P Value Reason for aspiration no. (%) 0.07 Induced abortion 253 (98.1) 302 (95.3) Spontaneous abortion 5 (1.9) 15 (4.7) Chlamydia screen positive 9 (3.5) 10 (3.2) 0.82 Gestational age no. (%) days 73 (28.3) 105 (33.1) days 111 (43.0) 128 (40.4) days 73 (28.3) 84 (26.5) IUD type chosen no. (%) 0.81 LNG-IUS 199 (77.1) 249 (78.5) Copper IUD 59 (22.9) 68 (21.5) History of any sexually transmitted infection no. (%) 79 (30.6) 90 (28.4) 0.56 History of chlamydia no. (%) 39 (15.1) 49 (15.5) 0.89 History of pelvic inflammatory disease no. (%) 7 (2.7) 7 (2.2) 0.70 * Plus minus values are means ±SD. IUD denotes intrauterine device, and LNG-IUS levonorgestrel intrauterine system. All P values were calculated with the use of the chi-square test or Student s t-test, as appropriate. Race or ethnic group was self-reported. Body-mass index is the weight in kilograms divided by the square of the height in meters. Data point for one woman in the immediate-insertion group was missing. Chlamydia nucleic acid amplification screening was performed immediately before the uterine aspiration procedure in 245 subjects in the immediate-insertion group and 304 subjects in the delayed-insertion group; 26 subjects (4.5%) were not screened for chlamydia before the aspiration procedure. There were no significant differences in demographic or baseline clinical characteristics between the randomized groups (Table 1). IUDs were in serted in all 258 women in the immediateinsertion group (100%) and in all 226 women in the delayed-insertion group who returned for their insertion visit (71.3%) (difference, 28.7 percentage points; 95% confidence interval [CI], 23.7 to 33.7; P<0.001). At least one follow-up visit was completed by 235 subjects (91.1%) in the immediate-insertion group and 258 (81.4%) in the delayed-insertion group, and complete 6-month data were available for 194 subjects (75.2%) and 231 subjects (72.9%), respectively. In both groups of women who received an IUD, those who were younger, had a lower income, or were Hispanic were less likely to complete the 6-month follow-up. (Baseline characteristics of women who completed follow-up and those who did not among subjects who underwent immediate or delayed IUD insertion, as well as among those in the delayed-insertion group who did not undergo insertion, are summarized in the Supplementary Appendix.) Outcomes Expulsions occurred in 13 women (5.0%; 95% CI, 2.7 to 8.5) in the immediate-insertion group and 6 (2.7%; 95% CI, 1.0 to 5.7) in the delayed-insertion group (absolute difference, 2.3 percentage points; 95% CI, 1.0 to 5.8) (Table 2). Of these expulsions, 13 were partial expulsions that were diagnosed by ultrasonography. All but 1 of these women noted symptoms (e.g., increased cramping, lengthening strings, or the IUD itself at the cervix) for which they were evaluated at extra (unscheduled) visits. There were 6 complete expulsions, all of which were recognized and reported by the subjects. Fifteen expulsions (78.9%) occurred within 2 months of insertion (Fig. 2). In multivariate analyses, the only factor significantly associated with expulsion was the body-mass index; a higher bodymass index was associated with higher odds of expulsion in both groups. Of the 13 subjects in the immediate-insertion group who had an expulsion, 7 requested and received a second IUD. Of these subjects, 5 (71%) had a second expulsion, 1 requested removal of the IUD, and 1 still had the IUD in place at the last n engl j med 364;23 nejm.org june 9,
7 T h e n e w e ngl a nd j o u r na l o f m e dic i n e Table 2. Outcomes of Immediate versus Delayed IUD Insertion after Uterine Aspiration.* Outcome Immediate Insertion Delayed Insertion P Value no./total no. (%) Difference in Percentage Points (95% CI) Risk Ratio (95% CI) Insertion 258/258 (100) 226/317 (71.3) < (23.7 to 33.7) 1.40 (1.31 to 1.50) LNG-IUS 199/258 (77.1) 178/226 (78.8) Copper IUD 59/258 (22.9) 48/226 (21.2) Expulsion 13/258 (5.0) 6/226 (2.7) ( 1.0 to 5.8) 1.90 (0.73 to 4.91) Partial 8/258 (3.1) 5/226 (2.2) Complete 5/258 (1.9) 1/226 (0.4) By type of IUD LNG-IUS 11/199 (5.5) 6/178 (3.4) Copper IUD 2/59 (3.4) 0/48 Removal 16/258 (6.2) 11/226 (4.9) ( 2.7 to 5.4) 1.27 (0.60 to 2.69) LNG-IUS 10/199 (5.0) 8/178 (4.5) Copper IUD 6/59 (10.2) 3/48 (6.2) Reinsertion After expulsion 7/13 (53.8) 0/6 After removal 2/16 (12.5) 0/11 Use at 6 months 179/194 (92.3) 177/231 (76.6) < (8.7 to 21.9) 1.20 (1.11 to 1.31) LNG-IUS 143/152 (94.1) 139/148 (93.9) Copper IUD 36/42 (85.7) 38/41 (92.7) * IUD denotes intrauterine device, LNG-IUS levonorgestrel intrauterine system, and NA not applicable. All P values were calculated with the use of the chi-square test. Insertion rates are based on all subjects who underwent randomization. Expulsion and removal rates at 6 months are based on all subjects who had an IUD inserted at any time after randomization. The type of IUD did not differ significantly within the immediate-insertion group or within the delayed-insertion group. Numbers are totals for partial and complete expulsions. Rates of use at 6 months are based on subjects for whom 6-month follow-up data were available. IUD-specific use at 6 months is based on subjects who had an IUD insertion and had 6-month follow-up data. NA contact. None of the 6 subjects in the delayedinsertion group who had an expulsion requested a second IUD. At 6 months, the IUD utilization rate was significantly higher in the immediate-insertion group than in the delayed-insertion group (92.3% vs. 76.6%, P<0.001). The frequency of requests for IUD removal due to cramping or pain was similar in the two groups (Table 2). Of the 27 subjects who requested removal after initial insertion, only 2 (both in the immediate-insertion group) requested reinsertion; both still had the IUD in place at 6 months. Among subjects in the delayed-insertion group who never received an IUD, the most common alternative choices for contraception were condoms (in 31.9%) and no method (in 25.2%). During the 6 months of follow-up, there were no pregnancies in the immediate-insertion group, as compared with five in the delayed-insertion group (P = 0.07), all among women who never received an IUD. Two of the three subjects who did not undergo randomization completed the 6-month followup; neither received an IUD, and one became pregnant. Adverse Events There were no significant differences between groups in rates of any adverse events, including pelvic infection (Table 3). No IUD perforations were noted. Two women (0.8%) in the immediate-insertion group and three (0.9%) in the delayed-insertion group had an incomplete abortion and required 2214 n engl j med 364;23 nejm.org june 9, 2011
8 Timing of IUD Insertion after Uterine Aspiration 100 Delayed-insertion group 90 Immediate-insertion group No Expulsion (%) Delayed-insertion group Immediate-insertion group P=0.18 by log-rank test Months since Insertion Figure 2. Kaplan Meier Analysis of Time to IUD Expulsion. Tick marks in the inset indicate last contact with subjects at study completion. Most expulsions occurred within 2 months after insertion (dashed vertical line). a repeat uterine aspiration (P = 1.00). Both women in the immediate-insertion group had their IUDs removed before reaspiration; neither required hospitalization or elected IUD reinsertion. All three women in the delayed-insertion group underwent reaspiration before the scheduled visit for IUD insertion. One woman (0.4%) in the immediateinsertion group had a failed abortion, with an ongoing pregnancy that was diagnosed at 21 weeks. She chose to continue the pregnancy and had an uncomplicated repeat cesarean section at 36 weeks, after the onset of spontaneous labor. The IUD was removed at that time, and she chose to undergo tubal ligation. A total of 10 pelvic infections were reported, 5 in each group (Table 3). Of 19 women whose screening tests for chlamydia were positive before uterine aspiration, 1 woman (in the immediateinsertion group) later received a diagnosis of pelvic infection. She was treated with antibiotics on an outpatient basis and did not have the IUD removed. Three subjects who tested negative for chlamydia before the procedure (2 in the immediate-insertion group and 1 in the delayed-insertion group) later received a diagnosis of pelvic infection and required intravenous antibiotics. The IUDs were removed from the 2 subjects in the immediateinsertion group; the subject in the delayed-insertion group had not yet received an IUD. Six additional women who tested negative for chlamydia before the procedure (2 in the immediate-insertion group and 4 in the delayed-insertion group) later received a diagnosis of pelvic infection and were treated with antibiotics on an outpatient basis; 5 did not have the IUD removed, and 1 had not yet received an IUD. Discussion This trial showed that when IUD insertion is performed immediately after first-trimester uterine aspiration, the rate of IUD expulsion, although higher than that with delayed insertion, is low and statistically noninferior to the rate with delayed insertion. Our results are compatible with an expulsion rate for immediate insertion that is 1.0 percentage point lower to 5.8 percentage points higher than that for delayed insertion. In addi- n engl j med 364;23 nejm.org june 9,
9 T h e n e w e ngl a nd j o u r na l o f m e dic i n e Table 3. Adverse Events in the Immediate-Insertion and Delayed-Insertion Groups. Adverse Event Immediate Insertion (N = 258) Delayed Insertion (N = 317) P Value* number (percent) IUD uterine perforation Diagnosis of pelvic infection after aspiration 5 (1.9) 5 (1.6) 0.76 Incomplete abortion 2 (0.8) 3 (0.9) 1.0 Failed abortion, ongoing pregnancy 1 (0.4) * All P values were calculated with the use of Fisher s exact test. One woman in the immediate-insertion group and none in the delayed-insertion group were positive for chlamydia at the time of aspiration. tion, immediate insertion was associated with significantly higher rates of IUD use at 6 months, with no increase in the risk of adverse events, including uterine perforation and pelvic infection. Pelvic infection was uncommon after IUD insertion, even in women with a history of pelvic inflammatory disease or positive screening results for chlamydia at the time of aspiration. These findings support the expansion of access to IUDs after first-trimester uterine aspiration, including elimination of an additional visit to test for sexually transmitted infection when no infection is clinically evident. In addition, these data add to the growing body of evidence supporting the safety and effectiveness of IUD use among a wider range of women who previously may not have been considered good candidates for an IUD. The IUD is among the most effective reversible contraceptive methods; the failure rate with typical use is 0.1 to 0.8% in the first year, which is similar to the failure rate with female sterilization. 1 In contrast, 9% of first-time users of combined oral contraceptives become pregnant in the first year. 1 The majority of subjects in the delayed-insertion group who did not return for an IUD chose a substantially less effective contraceptive method than an IUD, or they used no contraception. Our results confirm previously published data showing that 25 to 68% of women who make an appointment for IUD placement after an abortion do not return. 7,9,11,17 In the present trial, five pregnancies occurred in the delayed-insertion group, as compared with none in the immediate-insertion group, and all pregnancies occurred in women not using IUDs. Although this difference was not statistically significant, our study was not powered for this outcome and involved only 6 months of follow-up. A greater cumulative effect would be expected over a longer period. A limitation of the study is the substantial loss to follow-up, with 6-month follow-up rates of 73% in the immediate-insertion group and 75% in the delayed-insertion group. However, ongoing contact with women who have undergone an abortion is difficult. Many women travel far for abortion care. 18 They also wish to maintain their privacy, and many decline follow-up. 8,19 The high rates of loss to follow-up may have resulted in underestimation of rates of expulsion, unintended pregnancy, and infection. Also, women who did not return for follow-up had characteristics (e.g., younger age and lower income) that are associated with an increased risk of unintended pregnancy. Given the similar overall rates of loss to follow-up, we would expect rates of underreporting to be similar in the two groups for all outcomes except unintended pregnancy, which may have been more frequent in the delayed-insertion group (because women who did not return for IUD insertion may have been at higher risk for unintended pregnancy). The majority of the expulsions were identified during the first 2 months, and the time to expulsion was similar in the two groups (Fig. 2), findings that are consistent with previous data showing that most expulsions occur during this time frame. 20 Because later study contacts involved selfreporting of IUD expulsion or removal, it is possible that IUD expulsion was underreported. However, unrecognized expulsion is rare (estimated to account for <1% of expulsions), 21 and the accuracy 2216 n engl j med 364;23 nejm.org june 9, 2011
10 Timing of IUD Insertion after Uterine Aspiration of self-reports would not be expected to differ between groups. Mathematical modeling suggests that a switch from delayed IUD insertion to immediate insertion could prevent more than 70,000 unintended pregnancies annually in the United States. 3 However, the availability of immediate IUD insertion is restricted by federal funding for contraceptive use, such as Title X and state Medicaid waiver programs, because the provision of contraceptive services on the day of an abortion in the same facility is prohibited. Such policies that require health care providers to separate contraception provision from abortion provision reduce the likelihood that women will obtain the contraception needed to prevent unintended pregnancy. In summary, IUD insertion immediately after first-trimester induced or spontaneous abortion was associated with a risk of expulsion that was slightly higher but statistically noninferior to that associated with delayed insertion, and with similarly low complication rates. In addition, women assigned to immediate insertion had higher insertion rates and higher rates of IUD use at 6 months, effects that are likely to result in reduced rates of unintended pregnancy. Supported by a grant from the Susan Thompson Buffett Foundation. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. We thank Hong Li, M.P.H., Zunqiu Chen, M.S., Motomi Mori, Ph.D., and Nichole Carlson, Ph.D., of the Oregon Clinical and Translational Research Institute for statistical support. References 1. Trussell J. Contraceptive failure in the United States. Contraception 2004;70: Hubacher D, Cheng D. Intrauterine devices and reproductive health: American women in feast and famine. Contraception 2004;69: Reeves MF, Smith KJ, Creinin MD. Contraceptive effectiveness of immediate compared with delayed insertion of intrauterine devices after abortion: a decision analysis. Obstet Gynecol 2007;109: [Erratum, Obstet Gynecol 2007;110: 936.] 4. Heikinheimo O, Gissler M, Suhonen S. Age, parity, history of abortion and contraceptive choices affect the risk of repeat abortion. Contraception 2008;78: Goodman S, Hendlish SK, Reeves MF, Foster-Rosales A. Impact of immediate postabortal insertion of intrauterine contraception on repeat abortion. Contraception 2008;78: Marrs RP, Kletzky OA, Howard WF, Mishell DR Jr. Disappearance of human chorionic gonadotropin and resumption of ovulation following abortion. Am J Obstet Gynecol 1979;135: Stanek AM, Bednarek PH, Nichols MD, Jensen JT, Edelman AB. Barriers associated with the failure to return for intrauterine device insertion following firsttrimester abortion. Contraception 2009;79: Drey EA, Reeves MF, Ogawa DD, Sokoloff A, Darney PD, Steinauer JE. Insertion of intrauterine contraceptives immediately following first- and second-trimester abortions. Contraception 2009;79: El-Tagy A, Sakr E, Sokal DC, Issa AH. Safety and acceptability of post-abortal IUD insertion and the importance of counseling. Contraception 2003;67: Grimes DA, Lopez LM, Schulz KF, Stanwood NL. Immediate postabortal insertion of intrauterine devices. Cochrane Database Syst Rev 2010;6:CD Pakarinen P, Toivonen J, Luukkainen T. Randomized comparison of levonorgestrel- and copper-releasing intrauterine systems immediately after abortion, with 5 years follow-up. Contraception 2003;68: Gillett PG, Lee NH, Yuzpe AA, Cerskus I. A comparison of the efficacy and acceptability of the Copper-7 intrauterine device following immediate or delayed insertion after first-trimester therapeutic abortion. Fertil Steril 1980;34: World Health Organization, Task Force on Intrauterine Devices for Fertility Regulation, Special Programme of Research, Development and Research Training in Human Reproduction. IUD insertion following termination of pregnancy: a clinical trial of the TCu 220C, Lippes loop D, and copper 7. Stud Fam Plann 1983;14: Idem. IUD insertion following spontaneous abortion: a clinical trial of the TCu 220C, Lippes loop D, and copper 7. Stud Fam Plann 1983;14: D Agostino RB, Chase W, Belanger A. The appropriateness of some common procedures for testing the equality of two independent binomial proportions. Am Stat 1988;42: Upton GJG. A comparison of alternative tests for the 2 2 comparative trial. J R Stat Soc [A] 1982;145: Stanwood NL, Grimes DA, Schulz KF. Insertion of an intrauterine contraceptive device after induced or spontaneous abortion: a review of the evidence. BJOG 2001; 108: Jones RK, Zolna MRS, Henshaw SK, Finer LB. Abortion in the United States: incidence and access to services, Perspect Sex Reprod Health 2008;40: Rose SB, Lawton BA, Brown SA. Uptake and adherence to long-acting reversible contraception post-abortion. Contraception 2010;82: Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994;49: Backman T, Rauramo I, Huhtala S, Koskenvuo M. Pregnancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol 2004;190:50-4. Copyright 2011 Massachusetts Medical Society. n engl j med 364;23 nejm.org june 9,
Medical criteria for IUCD s Based on the WHO MEC (2004- Annexure 3) system a woman s eligibility for IUCD insertion falls in 4 categories. These categ
CLIENT ASSESSMENT Ensure that the woman is not pregnant Determine the length and direction of uterus. Ensure that she does not have gonorrhea and chlamydia, and is not a high risk case of STI s Identify
Migration of an intrauterine contraceptive device to the sigmoid colon: a case report
The European Journal of Contraception and Reproductive Health Care 2003;8:229 232 Case Report Migration of an intrauterine contraceptive device to the sigmoid colon: a case report Ü. S. nceboz, H. T. Özçakir,
This Protocol is adapted from the University of Colorado Protocol dated August 26, 2009.
Protocol for Post-Placental IUD insertion July 14, 2010 This Protocol is adapted from the University of Colorado Protocol dated August 26, 2009. Background Post-placental intrauterine device (IUD) insertion
Family Planning Curriculum
Family Planning Curriculum University of Alabama at Birmingham Department of Obstetrics and Gynecology Module 1: Introduction Incidence of unintended pregnancy and abortion Safety of abortion, morbidity
Intrauterine Device (IUD) THE FACTS
Intrauterine Device (IUD) Quick Facts Effectiveness in Preventing Pregnancy: Use: Of 100 women using IUDs for a year, about one may become pregnant. IUDs are better at preventing pregnancy than condoms,
NovaSure: A Procedure for Heavy Menstrual Bleeding
NovaSure: A Procedure for Heavy Menstrual Bleeding The one-time, five-minute procedure Over a million women 1 have been treated with NovaSure. NovaSure Endometrial Ablation (EA) is the simple, one-time,
STANDARD APRN PROTOCOL FOR IUD INSERTION: Levonorgestrel (LNG) Releasing Intrauterine System
STANDARD APRN PROTOCOL FOR IUD INSERTION: Levonorgestrel (LNG) Releasing Intrauterine System DEFINITION The LNG-releasing intrauterine systems (Mirena, Liletta and Skyla ) are on the market. The LNG-releasing
Young Women and Long-Acting Reversible Contraception. Safe, Reliable, and Cost-Effective Birth Control
ISSUES AT A GLANCE Young Women and Long-Acting Reversible Contraception Safe, Reliable, and Cost-Effective Birth Control In 2012, the American College of Obstetricians and Gynecologists (ACOG) revised
Objective. Indications for IUDs. IUDs 3 types. ParaGard IUD. Mirena IUD. Sonographic Evaluation of Intrauterine Devices (IUDs) Inert
Sonographic Evaluation of Intrauterine Devices (IUDs) Anna S. Lev-Toaff, MD FACR Department of Radiology Hospital of the University of Pennsylvania Philadelphia, Pennsylvania Leading Edge in Diagnostic
IMAP Statement on Safe Abortion
International Planned Parenthood Federation IMAP Statement on Safe Abortion Key points: When performed early in pregnancy by trained health personnel in adequate facilities, abortion is a very safe procedure
Insurance Reimbursement for Post-Pregnancy Long-Acting Reversible Contraception (LARC) Background Benefits of LARC
Insurance Reimbursement for Post-Pregnancy Long-Acting Reversible Contraception (LARC) Shandhini Raidoo MD, Bliss Kaneshiro MD, MPH, Mary Tschann MPH, Reni Soon MD, MPH, Emmakate Friedlander MD, Jennifer
MHRI IUD Protocol. Migraine with aura Current DVT or PE History of or current breast cancer Active viral hepatitis Severe cirrhosis or liver tumors
Table of Contents A. Indications B. Contraindications C. Prior to Insertion D. Insertion E. Follow-Up Visit F. Removal G. Re-Insertion H. Complications/Side Effects I. Appendices MHRI IUD Protocol A. Indications
Safe & Unsafe. abortion
Safe & Unsafe Facts About abortion WHAT IS THE DIFFERENCE BETWEEN UNSAFE AND SAFE ABORTION? What is unsafe abortion? Unsafe abortion is a procedure for terminating an unplanned pregnancy either by a person
Clinical Interruption of Pregnancy (Medical/Surgical Abortion)
Clinical Interruption of Pregnancy (Medical/Surgical Abortion) Approximately one fifth of all pregnancies in the United States end in abortion (Ventura et al., 2009). According to the CDC (2011a), there
Effective long-lasting strategy to prevent unintended pregnancy. The intrauterine system for contraception after abortion.
Effective long-lasting strategy to prevent unintended pregnancy. The intrauterine system for contraception after abortion. After the abortion I started re-thinking my birth control method. I am looking
Coding for the Contraceptive Implant and IUDs
LARC Quick Coding Guide 2012 UPDATE Coding for the Contraceptive Implant and IUDs CRECT CODING can result in more appropriate compensation for services. To help practices receive appropriate payment for
NORTHAMPTONSHIRE INTEGRATED SEXUAL HEALTH SERVICES IUD/IUS PROTOCOL
NORTHAMPTONSHIRE INTEGRATED SEXUAL HEALTH SERVICES IUD/IUS PROTOCOL Policy Details NHFT document reference MMPr005 Version Final Date Ratified 19.01.16 Ratified by Medicines Management Committee Implementation
Lippes Loop intrauterine device left in the uterus for 50 years. Case report
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Lippes Loop intrauterine device left in the uterus for 50 years Case report Background.The first Lippes Loop intrauterine device was distributed in 1962. It was a
LIPPES LOOP TRADEMARK. your intrauterine contraceptive
LIPPES LOOP TRADEMARK your intrauterine contraceptive LIPPES LOOP Patient Information This brochure provides information on the use of In trauterine Contraceptive Devices (lud s). There are other birth
Copper-Bearing Intrauterine Device
CHAPTER 9 Copper-Bearing Intrauterine Device This chapter describes primarily the TCu-380A intrauterine device (for the Levonorgestrel Intrauterine Device, see p. 157). Key Points for Providers and Clients
Fast Track to IVF. Objectives
Disclosure statement: Richard H. Reindollar, M.D. has no relevant financial relationships with any manufacturers of pharmaceuticals, laboratory supplies, or medical devices. Fast Track to IVF Richard H.
The Minnesota Chlamydia Strategy: Action Plan to Reduce and Prevent Chlamydia in Minnesota Minnesota Chlamydia Partnership, April 2011
The Minnesota Chlamydia Strategy: Action Plan to Reduce and Prevent Chlamydia in Minnesota Minnesota Chlamydia Partnership, April 2011 Section 5: Screening, Treating and Reporting Chlamydia While the information
Contraceptive Choice & Reducing Unplanned Pregnancy. Dr Paula Briggs Consultant in Sexual & Reproductive Health, UK
Contraceptive Choice & Reducing Unplanned Pregnancy Dr Paula Briggs Consultant in Sexual & Reproductive Health, UK Demographics Liverpool, UK Conflicts Dr Paula Briggs has received funding from: MSD Bayer
MECHANISM OF ACTION. Fertility Awareness-Based Methods. Victoria H. Jennings, PhD Marcos Arevalo, MD, MPH Deborah Kowal, MA, PA
Fertility Awareness-Based Methods Victoria H. Jennings, PhD Marcos Arevalo, MD, MPH Deborah Kowal, MA, PA Fertility awareness helps couples understand how to avoid pregnancy or how to become pregnant.
A Quick Reference Guide for Clinicians
A Quick Reference Guide for Clinicians Association of Reproductive Health Professionals This Quick Reference Guide for Clinicians presents a summary of scientific information about manual vacuum aspiration
Acute pelvic inflammatory disease: tests and treatment
Acute pelvic inflammatory disease: tests and treatment Information for you Information for you Published August 2010 Published in August 2010 (next review date: 2014) Acute What is pelvic inflammatory
Keywords: Efficacy, Misoprostol Vaginal Administration, Pregnancy
A COMPARISON OF EFFICACY AND SIDE-EFFECTS OF TWO METHODS OF VAGINAL MISOPROSTOL ADMINISTRATION IN THE FIRST TRIMESTER OF PREGNANCY TERMINATION FOR PATIENTS OF BANDARABAS HOSPITAL LOCATED IN IRAN *Azadeaskari,
Birth Control Options
1 of 5 6/2/2014 9:46 AM Return to Web version Birth Control Options What is contraception? Contraception means preventing pregnancy, also called birth control. Most people know about options such as birth
Comparison of oral versus vaginal misoprostol & continued use of misoprostol after mifepristone for early medical abortion
Indian J Med Res 122, August 2005, pp 132-136 Comparison of oral versus vaginal misoprostol & continued use of misoprostol after mifepristone for early medical abortion Suneeta Mittal, Sonika Agarwal,
IUD training principles 2013
IUD training principles 2013 Introduction These principles were developed in 2011 2012 by representatives and members of the following organisations: Sexual Health and Family Planning Australia (SHFPA)
Heavy menstrual bleeding and what you can do about it!
Heavy menstrual bleeding and what you can do about it! The intrauterine system as an alternative to hysterectomy. What is heavy menstrual bleeding? Do I have it? A woman s menstrual periods are considered
FEATURE. Adolescent Girls and Abortion
Adolescent Girls and Abortion Lawren Wellisch, MD; and Julie Chor, MD, MPH Abstract Abortion is an extremely common procedure in the United States, with approximately 2% of women having an abortion before
the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD your guide to
your guide to Helping you choose the method of contraception that is best for you IUD IUD the e IUD IU IUD the IUD 2 The intrauterine device (IUD) An IUD is a small plastic and copper device that is put
Prognosis of Very Large First-Trimester Hematomas
Case Series Prognosis of Very Large First-Trimester Hematomas Juliana Leite, MD, Pamela Ross, RDMS, RDCS, A. Cristina Rossi, MD, Philippe Jeanty, MD, PhD Objective. The aim of this study was to evaluate
Specimen collection and transport for Chlamydia trachomatis and Neisseria gonorrhoeae testing
Specimen collection and transport for Chlamydia trachomatis and Neisseria gonorrhoeae testing Overview Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections are two of the most common sexually
Frequently Asked Questions
Frequently Asked Questions What is Medabon? Medabon is a combination therapy for medical abortion. Medical abortion refers to the process of ending a pregnancy by taking medication, rather than through
Risk factors for IUD failure: results of a large multicentre case control study
Human Reproduction Vol.21, No.10 pp. 2612 2616, 2006 Advance Access publication June 14, 2006. doi:10.1093/humrep/del208 Risk factors for IUD failure: results of a large multicentre case control study
THE WELL. Intrauterine Contraceptive Devices WOMAN CENTRE
THE WELL WOMAN CENTRE Intrauterine Contraceptive Devices INTRAUTERINE CONTRACEPTIVE DEVICES How does the Mirena work? How effective is the Mirena? What are the advantages of the Mirena? What are the disadvantages
Chlamydia THE FACTS. How do people get Chlamydia?
What is Chlamydia? Chlamydia is a common bacterial infection that is sexually transmitted and often causes no symptoms. If not treated, chlamydia can damage reproductive organs and make it difficult for
Facts for Women Termination of pregnancy, abortion, or miscarriage management
Patient Education Facts for Women Termination of pregnancy, abortion, or miscarriage management This handout answers common questions about miscarriage management and the termination of a pregnancy, also
Nowrosjee Wadia Maternity Hospital
6. UNSAFE ABORTIONS The family planning programme of India is targeting towards providing a wide range of contraceptive choices to eligible couples with the ultimate objective of decreasing the unwanted
With 1.1 million induced abortions in the United
Original Research Incidence of Emergency Department Visits and Complications After Abortion Ushma D. Upadhyay, PhD, MPH, Sheila Desai, MPH, Vera Zlidar, MHS, Tracy A. Weitz, PhD, MPA, Daniel Grossman,
6.1 Contraceptive Knowledge and Practices of Women Requesting Medical Termination of Pregnancy
6. UNSAFE ABORTIONS Complications from unsafe abortions if untreated, could lead to morbidity or death. The best way to prevent unsafe abortions is to reduce the unmet need for contraception and make safe
IUD. the IUD. the IUD. the IUD. the IUD. the IUD. the IUD the IUD. the IUD. the the IUD. the IUD. the IUD. the IUD. the IUD. the IUD.
your guide to Helping you choose the method of contraception that is best for you I the IUD 2 3 The intrauterine device (IUD) An IUD is a small plastic and copper device that is put into your uterus (womb).
Information for you Abortion care
Information for you Abortion care Published in February 2012 This information is for you if you are considering having an abortion. It tells you: how you can access abortion services the care you can expect
Fadwa Almanakly, Pharm.D. Associate Director, Advertising and Promotions Bayer HealthCare Pharmaceuticals Inc. 6 West Belt Wayne, NJ 07470-6806
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Fadwa Almanakly, Pharm.D. Associate Director, Advertising and Promotions
Emergency contraception, including ellaone (based on FSRH/CEU Guidance)
Emergency contraception, including ellaone (based on FSRH/CEU Guidance) Dr Lynsey Dunckley Associate Specialist SRH Southampton Solent Sexual Health Conference Friday 25 th January 2013 Quiz! Which is
IUD. the IUD. the IUD. the IUD. the IUD. the IUD. the IUD. the IUD. the IUD. the IUD. your guide to
your guide to Helping you choose the method of contraception that is best for you IUD he the the the 2 3 The intrauterine device (IUD) An IUD is a small plastic and copper device that is put into your
BUTTE COUNTY PUBLIC HEALTH DEPARTMENT POLICY & PROCEDURE
BUTTE COUNTY PUBLIC HEALTH DEPARTMENT POLICY & PROCEDURE SUBJECT: Pregnancy Testing and Counseling Protocol P&P # APPROVED BY: EFFECTIVE DATE: Mark Lundberg MD Health Officer REVISION DATE: 2/20/2010 Phyllis
CODING GUIDELINES FOR CONTRACEPTIVES. Updated for ICD-10 CM (post October 1, 2015)
CODING GUIDELINES FOR CONTRACEPTIVES Updated for ICD-10 CM (post October 1, 2015) TABLE OF CONTENTS ICD-10 CM Diagnosis Codes: Encounter for contraception page 2 LARC: Coding for IUD Insertion and Removal
ALTERNATIVE TREATMENT PLAN AND CONSENT FOR MEDICAL ABORTION WITH MIFEPREX (MIFEPRISTONE) AND MISOPROSTOL
ALTERNATIVE TREATMENT PLAN AND CONSENT FOR MEDICAL ABORTION WITH MIFEPREX (MIFEPRISTONE) AND MISOPROSTOL The FDA gave its approval status to Mifepristone in 1996 based on research up to that time. Extensive
ESSURE REIMBURSEMENT GUIDE
ESSURE REIMBURSEMENT GUIDE A CODING AND COVERAGE RESOURCE Indication Essure is indicated for women who desire permanent birth control (female sterilization) by bilateral occlusion of the fallopian tubes.
Quick Start a LARC: Contraception initiation and pregnancy test follow up
Quick Start a LARC: Contraception initiation and pregnancy test follow up Suzanne Pearson, Christina Inness, Mandy Johnson, Kathleen McNamee LARC long acting reversible contraception Implant 3 years IUD
This is Jaydess. Patient Information. What is Jaydess? How does Jaydess work?
, Patient Information This is Jaydess We hope that this brochure will answer your questions and concerns about Jaydess. What is Jaydess? Jaydess is an intrauterine device consisting of a hormone capsule
Medical termination of pregnancy and subsequent adoption of contraception
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Shankaraiah RH et al. Int J Reprod Contracept Obstet Gynecol. 2013 Sep;2(3):367-371 www.ijrcog.org pissn 2320-1770 eissn
May 2014 U.S. Teenage Pregnancies, Births and Abortions, 2010: National and State Trends by Age, Race and Ethnicity
May 2014 U.S. Teenage Pregnancies, Births and Abortions, 2010: National and State Trends by Age, Race and Ethnicity Kathryn Kost and Stanley Henshaw Table of Contents Introduction 2 Key Findings 2 Discussion
Induced Abortion. Dr. Anan Sacdpraseuth Mahosot Hospital
Induced Abortion Dr. Anan Sacdpraseuth Mahosot Hospital GFMER - WHO - UNFPA - LAO PDR Training Course in Reproductive Health Research Vientiane, 26 November 2009 Induced Abortion Introduction 40 to 60
Q: Who has abortions? Q: Who has abortions?
Q: Who has abortions? Q: Who has abortions? 1 A: Women who have abortions come from all racial, ethnic, socioeconomic, and religious backgrounds. Most abortions occur among women who are 20-24, low-income,
A Guide to Hysteroscopy. Patient Education
A Guide to Hysteroscopy Patient Education QUESTIONS AND ANSWERS ABOUT HYSTEROSCOPY Your doctor has recommended that you have a procedure called a hysteroscopy. Naturally, you may have questions about
Copper intra-uterine device (IUD)
Oxford University Hospitals NHS Trust Copper intra-uterine device (IUD) Page What is an inter-uterine device? 3 How does it work? 4 Would an IUD be suitable for me? 5 Are there any risks or complications?
Clinical Scenarios CODING AND BILLING 101. Daryn Eikner, Family Planning Council Ann Finn, Ann Finn Consulting
Clinical Scenarios CODING AND BILLING 101 Daryn Eikner, Family Planning Council Ann Finn, Ann Finn Consulting 1 Always remember Follow coding guidelines If you didn t write it down, it didn t happen The
Hysterosalpingography
Scan for mobile link. Hysterosalpingography Hysterosalpingography uses a real-time form of x-ray called fluoroscopy to examine the uterus and fallopian tubes of a woman who is having difficulty becoming
NEW YORK STATE Department of Health
1 NEW YORK STATE Department of Health MEDICAID FEE-FOR-SERVICE BILLING FOR FAMILY PLANNING WEBINAR JUNE 20, 2014 To view recorded webinar, go to: https://www3.gotomeeting.com/register/241775910 2 Welcome
Patient information leaflet for Termination of Pregnancy (TOP) / Abortion
Patient information leaflet for Termination of Pregnancy (TOP) / Abortion Families Division Options available If you d like a large print, audio, Braille or a translated version of this leaflet then please
Preventing unsafe abortion
Preventing unsafe abortion Fact sheet N 388 March 2014 Key facts Around 22 million unsafe abortions are estimated to take place worldwide each year, almost all in developing countries. Deaths due to unsafe
OBGYN Orientation & Billing Guide 9/22/2014
OBGYN Orientation & Billing Guide 2014 Welcome to Magnolia Health! We thank you for being part of or considering Magnolia s network of participating providers, hospitals, and other healthcare professionals.
Assessment of Fetal Growth
Assessment of Fetal Growth Unit / Trust: 1. INTRODUCTION The aim of this guideline template is to outline the methods used to assess fetal growth and the referral pathways utilising customised antenatal
Effects of Pregnancy & Delivery on Pelvic Floor
Effects of Pregnancy & Delivery on Pelvic Floor 吳 銘 斌 M.D., Ph.D. 財 團 法 人 奇 美 醫 院 婦 產 部 婦 女 泌 尿 暨 骨 盆 醫 學 科 ; 台 北 醫 學 大 學 醫 學 院 婦 產 學 科 ; 古 都 府 城 台 南 Introduction Pelvic floor disorders (PFDs) include
HIGHLIGHTS. U.S. Women s Use of Sexual and Reproductive Health Services: Trends, Sources of Care and Factors Associated with Use, 1995 2010.
May 2013 U.S. Women s Use of Sexual and Reproductive Health Services: Trends, Sources of Care and Factors Associated with Use, 1995 2010 Jennifer J. Frost HIGHLIGHTS n Seven in 10 U.S. women of reproductive
LARC Quick Coding Guide Supplement
LARC ICD-9 to ICD-10 Crosswalk Basic Implant Codes ICD-9 ICD-10 Codes Implant CPT Procedure Codes HCPCSII/JCode V25.5 Z30.018 Encounter for initial prescription of other contraceptives 11981 - insertion
Frequently Asked Questions
What does the product do? The Stork by Rinovum Women s Health bridges the gap between natural intercourse and more aggressive, costly treatments, like IUI or IVF. The Stork is a home conception kit that
Cornual ruptured pregnancy with placenta increta CORNUAL RUPTURED PREGNANCY WITH PLACENTA INCRETA A RARE CASE
142 CORNUAL RUPTURED PREGNANCY WITH PLACENTA INCRETA A RARE CASE Agarwal NR 1, Rani A 1 *, Batra S 1 1. Department of Obststetrics and Gynaecology, Institute of Medical Sciences, Banares Hindu Univarsity.
Unintended pregnancy and induced abortion in a town with accessible family planning services: The case of Harar in eastern Ethiopia
Original article Unintended pregnancy and induced abortion in a town with accessible family planning services: The case of Harar in eastern Ethiopia Solomon Worku 1, Mesganaw Fantahun 2 Abstract Introduction:
49. INFANT MORTALITY RATE. Infant mortality rate is defined as the death of an infant before his or her first birthday.
49. INFANT MORTALITY RATE Wing Tam (Alice) Jennifer Cheng Stat 157 course project More Risk in Everyday Life Risk Meter LIKELIHOOD of exposure to hazardous levels Low Medium High Consequences: Severity,
BACKGROUNDER CONTRACEPTION
BACKGROUNDER CONTRACEPTION DID YOU KNOW?» Approximately 85 out of 100 sexually active women who are not using any contraceptive method will get pregnant within one year. 1» Worldwide 38% of women who become
abortion your questions answered
abortion your questions answered About Marie Stopes International Marie Stopes International is a specialist reproductive healthcare organisation and a registered charity working in both the UK and overseas.
No. 125 April 2001. Enhanced Surveillance of Maternal Mortality in North Carolina
CHIS Studies North Carolina Public Health A Special Report Series by the 1908 Mail Service Center, Raleigh, N.C. 27699-1908 www.schs.state.nc.us/schs/ No. 125 April 2001 Enhanced Surveillance of Maternal
Anatomy and Physiology of Human Reproduction. Module 10a
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
The Morning-After Pill: The Dangers of Over-the-Counter Availability
The Morning-After Pill: The Dangers of Over-the-Counter Availability Hanna Klaus, M.D. ABSTRACT: In response to a request by Barr Laboratories to market their emergency contraceptive Plan B across the
Post-Coital Hormonal Contraception Instructions for Use of Plan B, Plan B One-Step, Next Choice One Dose, My Way, Generic Levonorgestrel and Ella
Post-Coital Hormonal Contraception Instructions for Use of Plan B, Plan B One-Step, Next Choice One Dose, My Way, Generic Levonorgestrel and Ella Several options for emergency birth control exist for women
